BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 10235445)

  • 1. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration.
    Gori AM; Pepe G; Attanasio M; Falciani M; Abbate R; Prisco D; Fedi S; Giusti B; Brunelli T; Giusti B; Brunelli T; Comeglio P; Gensini GF; Neri Serneri GG
    Thromb Haemost; 1999 Apr; 81(4):589-93. PubMed ID: 10235445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
    Falciani M; Gori AM; Fedi S; Chiarugi L; Simonetti I; Dabizzi RP; Prisco D; Pepe G; Abbate R; Gensini GF; Neri Serneri GG
    Thromb Haemost; 1998 Mar; 79(3):495-9. PubMed ID: 9531029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation.
    Shimura M; Wada H; Wakita Y; Nakase T; Hiyoyama K; Nagaya S; Mori Y; Shiku H
    Am J Hematol; 1996 Jul; 52(3):165-70. PubMed ID: 8756081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man.
    Hansen JB; Sandset PM; Huseby KR; Huseby NE; Nordøy A
    Thromb Haemost; 1996 Nov; 76(5):703-9. PubMed ID: 8950777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
    Gosk-Bierska I; Wysokin Ski W; Karnicki K; Adamiec R
    Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term incubation with IL-4 and IL-10 oppositely modifies procoagulant activity of monocytes and modulates the surface expression of tissue factor and tissue factor pathway inhibitor.
    Paysant J; Soria C; Cornillet-Lefèbvre P; Nguyen P; Lenormand B; Mishal Z; Vannier JP; Vasse M
    Br J Haematol; 2005 Nov; 131(3):356-65. PubMed ID: 16225656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of tissue factor pathway inhibitor-1 on no-reflow in a rabbit model].
    Luo JG; Chen YD; Tian F; Wang CH; Lü Y; Yang XX; Lü SZ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Dec; 37(12):1113-8. PubMed ID: 20193184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels.
    Agledahl I; Brodin E; Svartberg J; Hansen JB
    Thromb Haemost; 2009 Mar; 101(3):471-7. PubMed ID: 19277407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microparticles (MPs), tissue factor (TF) and tissue factor inhibitor (TFPI) in cord blood plasma. A preliminary study and literature survey of procoagulant properties of MPs.
    Uszyński M; Zekanowska E; Uszyński W; Kuczyński J; Zyliński A
    Eur J Obstet Gynecol Reprod Biol; 2011 Sep; 158(1):37-41. PubMed ID: 21664032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome.
    Amengual O; Atsumi T; Khamashta MA; Hughes GR
    Thromb Haemost; 1998 Feb; 79(2):276-81. PubMed ID: 9493575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
    Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic-drug regimen in coronary artery stenting.
    Kopp CW; Steiner S; Priglinger U; Christ G; Probst P; Maurer G; Minar E; Huber K
    Blood Coagul Fibrinolysis; 2003 Jun; 14(4):379-86. PubMed ID: 12945880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease.
    Eling M; Stephens AC; Oragui EE; Rivers RP; Levin M
    Thromb Haemost; 2001 Feb; 85(2):240-4. PubMed ID: 11246540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration.
    Cella G; Cipriani A; Tommasini A; Rampin E; Sbarai A; Rocconi R; Mazzaro G; Luzzatto G
    Semin Thromb Hemost; 1997; 23(1):45-9. PubMed ID: 9156410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tissue factor and tissue factor pathway inhibitor during specific bronchial challenge in allergic asthma patients].
    Kemona-Chetnik I; Bodzenta-Lukaszyk A; Kucharewicz I; Rogalewska AM
    Przegl Lek; 2005; 62(2):98-101. PubMed ID: 16095153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Levels of plasma TF and TFPI activities in patients with acute leukemia].
    Zhu Y; Xie ZX; He XF; Han JZ; Li JC; He SL
    Hunan Yi Ke Da Xue Xue Bao; 2000 Aug; 25(4):401-2, 405. PubMed ID: 12206017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue factor and its inhibitor in human non-crescentic glomerulonephritis--immunostaining vs plasma and urinary levels.
    Naumnik B; Borawski J; Chyczewski L; Pawlak K; Mysliwiec M
    Nephrol Dial Transplant; 2006 Dec; 21(12):3450-7. PubMed ID: 16982632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
    Kojima T; Gando S; Kemmotsu O; Mashio H; Goda Y; Kawahigashi H; Watanabe N
    J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monocyte procoagulant activity induced by adherence to an artificial surface is reduced by end-point immobilized heparin-coating of the surface.
    Barstad RM; Hamers MJ; Møller AS; Sakariassen KS
    Thromb Haemost; 1998 Feb; 79(2):302-5. PubMed ID: 9493580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.